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1. Introduction and state of the art 
 
Metastasis, the process that results from cancer cells which spread through the body and generate new 
tumors at distant sites, is the cause of most of cancer-associated deaths. Indeed, most of the patients 
who suffer from metastatic disease cannot be cured by current therapeutic strategies(1). However, in 
contrast to the extensive knowledge acquired about the pathogenic mechanisms of primary tumor 
formation and development, the biological principles of metastasis remain obscure.  
 
Metastatic disease generation is a complex multi-step process named “metastatic cascade”. It consists 
of the invasion of cancer cells into the adjacent parenchyma, the intravasation of these cells into the 
bloodstream and their survival in circulation, the arrest and extravasation at distant organ sites and the 
colonization of these new tissue environments(2,3). Metastatic colonization involves the 
transformation of micrometastasis into clinically detectable lesions, named macrometastasis. It seems 
to be the most limiting step of the cascade, with an efficiency as low as 0.01%(4).  After traveling 
through the circulation, tumor cells find themselves in a new environment, distinct from the one 
present at the primary tumor site, to which they have to adapt to(5). The metastatic microenvironment, 
such as the primary tumor microenvironment, is composed of non-malignant cells, blood vessels, 
extracellular matrix and signaling factors which facilitate tumor progression(6,7).  
 
The first contribution to the elucidation of the role of the tumor microenvironment in the metastatic 
context was made by Paget more than a hundred years ago, when he postulated the “seed and soil 
hypothesis”. He observed that breast cancer dissemination was not random, but it obeyed a specific 
pattern. Thanks to that he came up with the idea that cancer cells (the “seed”) colonize specific organs 
which microenvironment (the “soil”) favors their settlement and proliferation, which means that not 
all foreign tissue microenvironments are suitable for metastatic progression(8). Subsequent studies 
showed that many cancer subtypes follow characteristic spreading patterns, fact that support the 
existence of organ-specific metastatic niches or “fertile soils”(9).  
 
Metastatic organotropism requires bidirectional interplay between the disseminated tumor cells and 
their host microenvironment. These cancer cells must undergo some phenotypic adaptation in order to 
form stable macrometastasis at distant sites(5). There is evidence that suggest that such adaptations 
are organ-specific, and they may thus partially depend on distinct signals emitted by the cells of the 
metastatic microenvironment. At the same time, cancer cells release factors which alter the metastatic 
microenvironment, as they do in primary tumor sites.  
 
One of the cell types which more actively enhances the abilities of cancer cells in primary tumors are 
cancer associated fibroblasts (CAFs), which are now considered as a central character in tumor 
progression, as they enhance tumorigenesis, tumor invasion, angiogenesis and metastasis 
processes(10,11). They are similar to myofibroblasts, normal cells involved in physiological programs 
of wound healing and fibrosis(12). Some examples of mediators secreted by CAFs are the hepatocyte 
growth factor (HGF), members of the epidermal growth factor (EGF) family, matrix-
metalloproteinases (MMPs) and various cytokines and chemokines(13). At the same time, tumor cells 
enhance the transformation of normal fibroblasts into CAFs through secretion of other factors, such as 
TGF-β(14). As it happens in primary tumors, fibroblasts of distant organ sites may also be important 
for metastasis development, but there are fewer studies which describe their functions in this context. 
These metastasis-associated fibroblasts (MAFs) may establish a fine-tuned crosstalk with cancer cells 
and potentiate their adaptation to the new microenvironment in an organ-specific manner. Indeed, 
O’Connell et al.  et al. reported that S100A4+ stromal cells, which are mainly fibroblasts, enhance 
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metastatic colonization through the secretion of several growth factors and ECM components, 
specially Tenascin-C and VEGF-A(15). However, the existence of specific molecules secreted by 
MAFs which may drive cancer specific metastatic colonization remains uncertain.  
 
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide(16). In 
addition, ∼20% of patients show metastasis at the time of diagnosis(17). CRC displays marked 
metastatic organotropism, being the liver the most common metastatic site, followed by the 
lung(18,19). The high frequency of liver metastasis can be easily explained by the design of the 
circulatory system, as the liver is the first organ encountered by CRC cells through the portal vein(3). 
By contrast, their predilection for the lung cannot be solely explained by a circulatory relationship. 
Therefore, there may be specific components in the lung microenvironment which mediate 
colonization of colorectal cancer cells and convert the lung tissue into a permissive “soil” for them. 
As fibroblasts comprise a great part of lung interstitial compartment(20), lung MAFs may contribute 
to “fertile soil” generation by secretion of specific molecules, which allow CRC cells metastatic lung 
colonization and enhance their malignant capabilities (Fig.1).  
 
 
 
 
Figure 1. Metastatic colonization of the lung. CRC cells travel through the bloodstream and extravasate by 
crossing the lung capillaries. In the lung microenvironment, they interact with various cell tipes, such as 
metastasis-associated fibroblasts (MAFs), NK cells, T cells, tumor-associated macrophages (TAMs) and 
dendritic cells. Tumor cells establish a fine-tuned crosstalk with MAFs, by releasing mediators such as TGFβ, 
enhancing MAFs tumor-promoting capabilities. In addition, MAFs secrete other mediators, such as Tenascin C, 
which stimulate CRC cells malignant skills. Self-created figure. 
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2. Hypothesis 
 
Our aim is to test the following hypothesis: pulmonary MAFs show a differential gene expression 
profile, which promotes CRC cells malignant skills and mediates their metastatic dissemination to the 
lung.  
 
3. Research objectives 
 
The global goal of this project is to disentangle the role of MAFs in CRC organ-specific 
dissemination to lung. Three specific aims are envisioned: 
 
 Aim 1 - To identify key mediators in MAFs-CRC cells lung metastasis-promoting 
communication. 
 
 Aim 2 - To elucidate the influence of MAF-specific molecules on CRC cells malignant 
abilities. 
 
 Aim 3 - To determine the contribution of MAF-specific molecules to lung metastatic 
colonization by CRC cells. 
 
 
4. Research methodology and approach 
 
4.1. Work Package 1 (WP1): Identifying key mediators in MAFs-CRC cells lung metastasis-
promoting communication (→ Aim 1). 
 
Approach: As mentioned above, in order to achieve lung colonization, CRC cells must undergo 
phenotypic adaptation, which may be facilitated by MAF-secreted molecules. These specific 
molecules may transform the lung microenvironment into a permissive niche suitable for tumor 
progression. However, there are no previous studies which define MAFs gene expression signature in 
colorectal lung metastasis. To characterize MAF-specific mediators, transcriptomes will be compared 
between MAFs and normal lung fibroblasts (NLFs) by transcriptomic microarray analysis of both cell 
types.  
 
Methods (Fig.2):  
Fibroblast isolation - MAFs and NLFs will be isolated from 8 patients with colorectal lung metastases 
subjected to complete pulmonary metastasectomy(21). These patients will show controlled primary 
tumors and no extrathoracic lesions, with the exception of hepatic lesions, according to the criteria for 
potentially curative operation(22). Before starting the procedure, written informed consent will be 
obtained from all the subjects. Tumor and normal lung tissue, which will be from as far from the 
tumor as possible, will be taken from the operating room, seared into small pieces and processed by 
collagenase digestion in order to obtain a single cell suspension. Then, NLFs and MAFs will be 
isolated by a method based on Fluorescence-Activated Cell Sorting (FACS) in which PDGFRα is 
used as a specific marker of both NFs and MAFs(23). After isolation and data processing by FACS 
sorter software (BD FACS Diva), cells can be either cultured (see 4.2) or lysed for RNA purification 
and further analysis.  
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Microarray analysis - After RNA extraction and integrity evaluation, complementary DNA will be 
synthesized from total RNA, then labeled with biotinylated nucleotides and assessed by hybridization 
to the Affymetrix U133A GeneChip. Data analysis will be performed using the Affymetrix 
Microarray Suite 5.0. Software. To find genes which define MAFs phenotype, we will discard those 
ones which expression do not change significantly between MAFs and NFs, and select those which 
are significantly overexpressed in MAFs samples. The statistical filters that will be used have been 
described by Kang et al.(24).  
 
Histological validation - The expression of the MAF-specific molecule previously identified will be 
evaluated on human lung tissue by immunohistochemistry. Colorectal lung metastasis and normal 
lung samples will be obtained from a tumor bank and compared. 
 
Expected outcome: From microarray data analysis we expect to identify few MAF-specific 
molecules. One of them will be selected for validation according to previous research evidence or 
database information. From histological validation we expect to find significantly higher expression 
of the assessed protein in lung metastatic lesions compared to normal lungs. If validation is 
successful, the molecule will be used for further experiments. If not, we will take into account this 
result and select another possible MAF-specific mediator from the microarray data analysis results.  
 
 
 
 
Figure 2. Work Package 1 summary. MAFs and NLFs will be isolated from tumor and normal tissue, 
respectively, from patients suffering from lung metastatic CRC disease. Total mRNA will be extracted from 
both cell types, complementary DNA will be synthetized and labeled, and subsequently hybridized to a DNA 
microarray chip.  After statistical analysis, differentially expressed genes in MAFs will be identified. Self-
created figure. 
  
 
4.2. Work Package 2 (WP2): Elucidating the influence of MAF-specific molecules on CRC cells 
malignant abilities (→ Aim 2). 
 
Approach: It is well know that CAFs play a crucial role in proliferation, invasiveness and 
angiogenesis of cancer. Thus, we hypothesize that MAFs are also relevant for malignant abilities 
acquisition by tumor cells. The effect of unaltered MAFs will be compared to the effect of siRNA-
transfected MAFs (MAF*s), which do not express the protein identified in 4.1. To test our hypothesis 
we will characterize CRC cells phenotype by using various in vitro assays after MAF or MAF*-
derived conditioned medium (MAF-CM/MAF*-CM) exposure of HCT 116 cells, a human colorectal 
adenocarcinoma cell line. The features that will be evaluated are the following: proliferation, invasion 
5 
 
and viability in presence of oxaliplatin, the main chemotherapeutic agent employed for the treatment 
of metastatic colorectal cancer(25).  
 
Methods (Fig.3):  
Primary culture of MAFs from patients: After fibroblast isolation by FACS (see 4.1), MAFs from 4 
patients will be plated uniformly on Petri dishes and cultured as previously described(26) in DMEM 
(Dulbecco’s Modified Eagle Medium, Gibco) culture medium supplemented with 10% fetal bovine 
serum at 37ºC, 5% CO2 atmosphere.  
 
MAF siRNA transfection: Half of MAF cultures will be transfected with siRNA in order to silence the 
expression of the MAF-specific mediator identified in 4.1., by using Fibroblast Transfection Kit from 
Altogen Biosystems following manufacturer’s instructions. Transfection and siRNA silencing 
efficiency will be assessed by western blot as previously described by Nolte et al.(27).  
 
MAF-CM and MAF*-CM production: For the production of both types of conditioned media, MAFs 
and MAF*s will be cultured in 2% fetal bovine serum-containing DMEM until they reach 80-90% 
confluence. After washing twice with Phosphate-Buffered Saline (PBS), fetal bovine serum-
containing medium will be changed by albumin-containing medium. Fibroblasts will be maintained 
under these conditions for 48 hours, allowing them to secrete soluble mediators into the environment. 
Eventually, both CM will be collected, centrifuged to remove dead cells and sterile filtered(28–31).  
 
Assessment of CRC cells skills: Every one of the following assays will be carried out by using the 
well characterized human adenocarcinoma cell line HCT 116. HCT 116 cells will be maintained in 
McCoy’s 5a medium (ATCC) supplemented with 10% fetal bovine serum, at 37ºC, 5% CO2 
atmosphere. Before each experiment, HCT 116 cells will be treated with MAF-CM of MAF*-CM and 
incubated for 48 hours(30).  
 
Proliferation assay: Proliferation of treated HCT 116 will be evaluated by the 5-bromo-2’-
deoxyuridine (BrdU) proliferation ELISA kit (Roche Diagnostics) according to the manufacturer’s 
instructions, as the most accurate method of measuring cell proliferation is an estimation of DNA-
synthesizing cells(32). BrdU is a thymidine analogue which can be detected by fluorescently labeled 
antibodies and subsequent flow cytometry. Cells will be seeded in 96-well plates and incubated with 
BrdU(33). The optical density will be measured at 405 nm and results will be compared between 
MAF-CM and MAF*-CM treated HCT 166 cells. 
 
Viability assay: HCT 116 cells viability will be assessed by the methyl thiazolyl tetrazolium (MTT) 
assay, a quantitative colorimetric method which evaluates metabolic activity or mitochondrial 
functionality. It consists on metabolic reduction of MTT to insoluble formazan by the  mitochondrial 
enzyme succinate dehydrogenase(34). After incubation with MAF-CM or MAF*-CM, cells will be 
seeded in 96-well plates and treated with increasing oxaliplatin concentrations (0.0001-1000µM) 
previously established by Lu et al.(35). 48 hours later, 10 μl of 5 mg/ml MTT salt (Sigma Aldrich) 
will be added to the cells, which will be incubated for 4 hours more. In order to solve the formazan 
colored crystals, MTT will be replaced by 10% sodium dodecyl sulphate solution(28). Finally, 
absorbance will be quantified at 575 nm with a microtiter plate reader, taking 690 nm as the reference 
wavelength to remove background signals(31). Absorbance values will be transformed into cell 
viability percentages by comparing them to the absorbance values of untreated cells (100% viability).  
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Invasion assay: CRC cell invasion assay will be done by using the “chemoinvasion assay”, first 
described by Albini et al. more than 30 years ago(36). It uses Matrigel, a soluble basement membrane 
extract prepared from an epithelial tumor in order to measure the invasive skills of tumor cells(37). 
The assay is performed in Boyden migration chambers, which consist in upper and lower 
compartments separated by a porous filter. An “attractant” is administered in the lower well, so if 
tumor cells are malignant, they will degrade the Matrigel layer and then migrate to the lower 
compartment(38). In this project, the invasive ability will be tested according to the procedure 
described by Both et al.(39). Briefly, after incubation with different CM, the culture media will be 
replaced by RPMI 1640 (Roswell Park Memorial Institute, Gibco). Perforated membranes will be first 
coated with fibronectin to promote attachment and then covered with Matrigel (gelatinized at 37ºC for 
20 minutes). Membranes will be assembled in a Boyden chamber and fetal bovine serum will be used 
as attractant. The upper chamber will be filled with RPMI medium and HCT 116 cells previously 
treated with different CM, and the system will be incubated for 40 hours. After removing the cells 
which do not accomplish migration, the membranes will be stained with crystal violet and the cells on 
the lower surface of the filter will be counted manually in five different microscopic fields. 
 
Expected outcome: We expect to find out that HCT 116 cells grown in the presence of MAF-CM 
have more robust tumor-promoting hallmarks than HCT 116 cells treated with MAF*-CM, as the 
second CM does not contain the mediator identified in 4.1. It will also be possible that such mediator 
confers specific abilities to CRC cells and so we will see significant differences in part of the 
experiments. If we do not find any differences between HCT 116 cells cultured in distinct conditions, 
the expression of the specific molecule by MAFs might be triggered by metastatic colorectal cancer 
cells as a consequence of lung colonization, and such protein might not exert any effect on tumor cells 
capabilities.  
 
 
 
Figure 3. Work Package 2 summary. Previously isolated MAFs will be transfected with siRNA in order to 
silence the MAF-specific mediator (MAF*s). Conditioned medium (CM) will be obtained from unaltered MAFs 
and MAF*s, to treat HCT 116 cells. Subsequently, treated HCT 116 cells will be subjected to different assays in 
order to characterize their malignant capabilities. Self-created figure. 
 
 
4.3. Work Package 3 (WP3): Determining the contribution of MAF-specific molecules to lung 
metastatic colonization by CRC cells (→ Aim 3). 
 
Approach: As mentioned above, CRC cancer patients with advanced disease show a non-random 
metastatic spreading pattern, being liver and lung the most commonly affected distant sites, in that 
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order. In contrast to the liver, the leading position of the lung cannot be simply explained by the 
circulatory system anatomy, and so it might be due to particularities of the pulmonary 
microenvironment.  In the last part of our project, we will try to elucidate if the presence of the 
mediator can explain at least partially the high frequency of pulmonary metastasis by playing a role in 
colonization. For this work, we will use a mouse model of metastatic CRC in which we will silence 
the expression of the mediator of interest in fibroblasts via conditional knockout technology. The 
occurrence and size of lung metastasis will be compared between ko mice and control mice, which 
fibroblasts express the mediator.  
 
Methods (Fig.4): 
Conditional knockout mice generation: 
In order to generate mice whose fibroblastic cells do not express the identified mediator, we will use 
Cre-lox recombination technology. It consists in the expression of a site-specific DNA recombinase 
(Cre) and the introduction of two loxP (loci of recombination) sites, which will be recognized by Cre. 
Recombination results in deletion of the loxP-flanked sequence, and subsequently, in the inactivation 
of the gene of interest(40). For this purpose, two transgenic mouse strains are needed: one mouse 
strain with a loxP-flanked gene segment (identified mediator), known as floxed mouse, and a second 
mouse strain expressing Cre recombinase in a specific organ, tissue or cell type (fibroblasts). In our 
study, the progeny obtained by crossing both strains will express Cre recombinase only in fibroblasts, 
where recombination between both loxP sites will take place and the expression of the MAF-specific 
mediator will be silenced. All mice used will be athymic nude mice, as the immunodeficiency is 
essential to generate the CRC metastatic model explained below. The mouse strain harboring our 
mediator flanked by loxP sites will be created by gene targeting in embryonic stem cells as described 
by Meyers et al.(41). On the other hand, the second mouse strain, which will express the Cre 
recombinase under the influence of Fibroblast-Specific Protein promoter (Fsp-Cre) will be generated 
as previously reported by Bhowmick et al.(42). Conditional ko mice will be compared to unaltered 
athymic nude mice.  
 
Metastatic CRC mouse model generation: Most genetically engineered CRC mouse models are not 
usually metastatic, fact that makes more difficult the study of this cancer stage. To solve this problem, 
Céspedes et al.(43) developed a technique based on orthotopic microinjection of human CRC cancer 
cells in nude mice, and they achieve metastatic foci generation in the most clinically relevant 
metastatic sites. Moreover, they characterized the metastatic potential of different human CRC cell 
lines, showing that HCT 116, which will be the cell line used in our project, generated lung metastasis 
in 50% of the mice. For our work, we will reproduce their orthotopic cell microinjection (OCMI) 
approach. Before starting the procedure, HCT 116 cells will be maintained as mentioned in 3.2. 
Briefly, four-week-old mice of both groups (ko and control) will be anesthetized with ketamine and 
xylazine, and their cecum will be exteriorized by laparotomy. HCT 116 cells will be suspended in 
DMEM and injected into the cecal wall by using an especially designed micropipette, described in 
their publication. The pipette must be introduced approximately 5 mm and with a 30º angle in order to 
obtain successful results. Finally, the intestine will be introduced into the peritoneal cavity and the 
incision will be closed with grapes. Mice will be maintained until death due to CRC or until the 
experiment finishes (120 days).  
 
In vivo detection of colorectal tumors: Primary colorectal tumors apparition and growth will be 
assessed by manual palpation of the abdominal zone of the animals(44).  In order to better 
characterize the primary tumors, once they have been detected, mice will be subjected to 
microcomputed tomography (microCT) colonography, as previously described by Pickhard et al.(45). 
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Mice will be anesthetized, and contrast material will be administered via the anal canal. Next, they 
will be scanned in the prone position by a microCT scanner (ImTek) by using the imaging parameters 
established in the publication.  Images will be analyzed by employing AMIRA software (Thermo 
Scientific), which will provide us 2D sagittal, axial and coronal cross-sectional images, and then 
evaluated by a well-trained researcher, who will be uninformed about the type of mouse which is 
being analized. The frequency and the size of colorectal tumors will be compared between control 
mice and conditional ko mice.  
 
In vivo detection of lung metastases: Mice which develop primary colorectal tumors will be next 
analyzed in order to detect the generation of lung metastases. In order to detect and measure lung 
metastatic masses, we will use microCT again, as it has been reported as a reliable non-invasive 
method of lung cancer progression monitoring in mice(46). Mice will be anesthetized and their chest 
area will be imaged by using a microCT scanner (ImTek). Images will be processed by AMIRA 
software and interpreted by an experienced researcher in a blinded manner.  
 
Survival analysis: The cumulative survival of control and conditional ko mice will be estimated 
according to the Kaplan and Meier method(47) and plotted versus days after injection. The results will 
be analyzed by using Stata 7.0 software.  
 
Expected outcome: We will expect that CRC incidence and primary tumor volume will not show 
significant differences between control and conditional ko mice, as the mediator is not expected to be 
involved in primary tumor formation but in metastatic colonization. Moreover, we will expect lung 
metastatic frequency and size to be higher in control mice, as they express the previously identified 
mediator. This result will mean that such molecule promotes lung colorectal cancer metastasis. In 
relation to the survival, we will expect it to be longer in ko mice, fact that will mean that the 
metastatic colonization process is partially impaired by the lack of the MAF-specific mediator.  
 
 
 
Figure 4. Work Package 3 summary. Conditional ko mice, whose fibroblasts do not express the previously 
identified mediator, will be generated by crossing a floxed mouse strain with a Cre mouse strain. Conditional ko 
mice and nude mice will be subjected to orthotopic cell microinjection (OCMI) of HCT 116 cells, directly into 
the cecal wall. Finally, primary colorectal tumor size and frequency, and lung metastases size and frequency will 
be assessed by microcomputed tomography. Survival will be analyzed according to Kaplan-Meier method. Self-
created figure. 
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5. Coherence and effectiveness of the work plan 
 
The project is structured in three work packages (WP), each related to its respective objective. All the 
WP are linked to each other, thus each has to be reached before starting the next one. The whole 
project has been planned to be carried out in 4 years by six researchers (three pre-doctoral students 
and three postdoctoral researchers) plus the principal investigator. Each pre-doc will work with a 
PhD, to favor the learning of the first ones and to increase the efficiency. Besides developing 
experimental procedures, all group members will attend various training activities, in order to speed 
the experimental set-up steps and get better quality results (Fig.5).  
 
 
 
 
 
Figure 5.  Work plan for the proposed project. Self-created figure. 
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6. Dissemination plan 
 
We will emphasize the spreading of the new knowledge generated by this project, as research 
dissemination is crucial for the progression of science. The primary ways of dissemination will be 
scientific publications in high impact international journals. Our work is likely to interest especially 
both doctors and biologists working on basic and translational cancer research; therefore we will 
select journals focused on these topics. Further, preliminary results will be presented by the group 
members at national and international conferences.  
In addition to classic dissemination approaches, our outcome will be spread through press and social 
media releases, in order to reach the general public.  
 
 
7. Discussion, conclusion and impact of the results 
 
We consider that lung MAFs are specialized cells with their own characteristics. If we find 
transcriptomic differences between MAFs and normal pulmonary fibroblasts, this idea will be 
strengthened, as divergent expression profiles normally imply distinct functional phenotypes. It is 
widely accepted that CAFs differ functionally from normal fibroblasts(10–13), but the relationship 
between CAFs and MAFs has to be investigated in the future. However, the main pitfall of these types 
of studies lies in fibroblast heterogeneity in cancer patients(48), fact which means that our expected 
results might not be valid for all patients, and that further studies with a larger sample size must thus 
be performed.  
Regarding the acquisition of malignant capabilities by CRC cells, we expect MAFs to act as 
enhancers, as CAFs do in primary tumors. If MAF-CM-treated tumor cells show higher proliferation 
rate, the mediator might facilitate the colonization of lung microenvironment in CRC patients, as 
transformation of pulmonary micrometastases into clinically detectable macrometastasis will occur in 
an easier way. What is more, it is known that chemoresistance to oxaliplatin happens to nearly all 
CRC patients(49). Therefore, if MAF*-CM-treated cells exhibit less viability when exposed to 
oxaliplatin than MAF-CM-treated cells, this could mean that MAFs contribute to resistance 
development. Finally, if MAF-CM-treated cells have a more invasive behavior, they might be more 
potentially metastatic in vivo, fact that would support the key role of the identified mediator in 
metastasis generation. 
In relation to in vivo experiments, we expect to inhibit or decrease the generation of CRC lung 
metastases by silencing the identified mediator. These results will mean that such mediator is relevant 
for lung colonization by CRC cells and will shed some light on the puzzle of organ-specific metastasis 
development and “fertile soil” generation. Moreover, it could be tested as a target in lung 
disseminated CRC treatment and might contribute to the development of novel metastasis-specific 
therapeutic approaches which could improve the survival of patients suffering from a disease that 
nowadays is considered as almost incurable(50).  
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